← All trials
NCT04358497
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2020
- Primary completion
- Jul 31, 2022
- Completion date
- Oct 1, 2022
- First posted
- Apr 24, 2020
- Last posted
- Apr 24, 2020
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hospital de Clínicas Dr. Manuel QuintelaLead sponsor
- Centro Cardiovascular UniversitarioOverall official - principal investigator
- Centro Cardiovascular UniversitarioCollaborator
- Hospital Pereyra Rossell, MontevideoCollaborator
- Hospital de Clínicas Dr. Manuel QuintelaReponsible party - principal investigator
- University of the Republic, UruguayCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.